Reporting: U.S. BIOSECURE Act

  1. Lower Court Agrees With WuXi AppTec (And Many Of Us) 8/14/2026

    A lower-court ruling does not make a victory. But it adds a little sanity to this melodrama. On August 7, a U.S. District Judge did something that has been surprisingly rare in the long-running WuXi AppTec/BIOSECURE Act saga: He looked at the U.S. government's case for labeling WuXi a “Chinese military company” and decided the government had not shown enough evidence. Analysis from Chief Editor Louis Garguilo.

  2. A (Partial) Vindication For Wuxi AppTec … And Global Outsourcing 10/22/2025

    Chief Editor Louis Garguilo believes WuXi AppTec should take this as a dose of vindication. Even a partial victory. Supporters persuaded the Senate to NOT include WuXi in the BIOSECURE Act. Here’s an analysis of this current situation that can affect anyone outsourcing drug development and manufacturing.

  3. Will It Not Die? The BIOSECURE Act Back With Iterations 10/17/2025

    Chief Editor Louis Garguilo describes this as "Act VI, in which the antagonist reenters the stage." The stage is the U.S. Senate, and the antagonist is again the BIOSECURE Act. Earlier this month, the Senate authored a new version of the legislation – again as an add on to a National Defense Authorization Act (NDAA). 

  4. BIOSECURE Act Starts Dismantling WuXi 10/16/2024

    Components of the WuXi global organization are for sale. It’s a forced divestiture. WuXi AppTec is marketing some of its U.S. and European operations. The ill-advised BIOSECURE Act targeting several China-based biopharma companies is having its intended effects, even before the legislation is fully passed by the U.S. government. Where do you stand?

  5. BIOSECURE Act Passes House. How Will It Impact Your Outsourcing? 9/10/2024

    The U.S. House of Representatives was hell-bent on sending a message to China – and all of us in the biopharma industry. Congress hopes that message – and real-life consequences – will be accomplished via its successfully passing the BIOSECURE Act in a House vote. Breaking analysis from Chief Editor Louis Garguilo. 

  6. Warning To U.S.-Based CDMOs: Don't Get Complacent 9/9/2024

    How could I not ask him for an opinion regarding our vigorously pursued editorials on the WuXi Apptec–BIOSECURE Act. After all, Reza Oliyai has outsourced a myriad of development and manufacturing services to hundreds of CDMOs around the world. He did so at Gilead for decades, and since as the CEO  of his eponymous consulting company. His response did not disappoint.

  7. Clinical Trials In China Reboot BIOSECURE Act 8/21/2024

    Clinical trials are not my beat, but the BIOSECURE Act targeting CDMOs sure is. Now the congressional committee involved with putting that legislation together has found something of perhaps more substance, and better substantiated, to add to the impetus of the Act: clinical trials in China.

  8. Breaking: BIOSECURE Act Out. Long Live Wuxi Apptec? 6/25/2024

    The U.S. House Rules Committee did not include the BIOSECURE Act in the final list of amendments for the National Defense Authorization Act (NDAA). Chief Editor Louis Garguilo has been outspoken in defending WuXi Apptec’s right to due process. Readers have responded in spades. Here's the latest.

  9. Assassination By Implication? Interview With WuXi AppTec (Part 2) 5/20/2024

    “As you read these accusations, it’s like an attempted death by a thousand implications,” says Rick Connell, former Pfizer supply-chain executive and current WuXi AppTec President, U.S. and Europe. In this part two, he provides a line-by-line analysis of the BIOSECURE Act targeting his company.

  10. Exclusive Interview: WuXi AppTec Responds To BIOSECURE Act 5/13/2024

    Rick Connell, WuXi AppTec’s President, U.S. and Europe, agreed to an exclusive interview with Chief Editor Louis Garguilo to address accusations in the BIOSECURE Act. To understand Connell is to understand the shock at WuXi AppTec – and  among its customers.